Drug intelligence / Profile preview

AZD8075

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD8075 is a small molecule drug candidate developed by AstraZeneca for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It acts as a CRTH2 antagonist, targeting the prostaglandin D2 receptor 2.

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on AZD8075.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD8075.

Explore the full profile